

## CLAIMS

1. An agent for the prevention or treatment of a disease associated with hyperglycemia, comprising as an active  
5 ingredient a selective SGLT1 inhibitor.
2. An agent for the prevention or treatment as claimed in claim 1, wherein the active ingredient is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
3. An agent for the prevention or treatment as claimed in  
10 claim 1 or 2, wherein the dosage form is an oral agent.
4. An agent for the prevention or treatment as claimed in any one of claims 1-3, wherein the disease associated with hyperglycemia is diabetes.
5. An agent for the prevention or treatment as claimed in  
15 claim 4, wherein the diabetes is postprandial hyperglycemia.
6. An agent for the prevention or treatment as claimed in any one of claims 1 to 3, wherein the disease associated with hyperglycemia is impaired glucose tolerance.
7. An agent for the prevention or treatment as claimed in  
20 any one of claims 1 to 3, wherein the disease associated with hyperglycemia is diabetic complications.
8. An agent for the prevention or treatment as claimed in any one of claims 1 to 3, wherein the disease associated with hyperglycemia is obesity.
- 25 9. A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of a selective SGLT1 inhibitor.

10. A method for the prevention or treatment as claimed in claim 9, wherein the selective SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

5 11. A method for the prevention or treatment as claimed in claim 9 or 10, wherein the dosage form is an oral agent.

12. A method for the prevention or treatment as claimed in any one of claims 9 to 11, wherein the disease associated with hyperglycemia is diabetes.

10 13. A method for the prevention or treatment as claimed in claim 12, wherein the diabetes is postprandial hyperglycemia.

14. A method for the prevention or treatment as claimed in any one of claims 9 to 11, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

15 15. A method for the prevention or treatment as claimed in any one of claims 9 to 11, wherein the disease associated with hyperglycemia is diabetic complications.

16. A method for the prevention or treatment as claimed in any one of claims 9 to 11, wherein the disease associated with  
20 hyperglycemia is obesity;

17. A use of a selective SGLT1 inhibitor for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia.

18. A use as claimed in claim 17, wherein the selective SGLT1  
25 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

19. A use as claimed in claim 17 or 18, wherein the composition

is an oral agent.

20. A use as claimed in any one of claims 17 to 19, wherein the disease associated with hyperglycemia is diabetes.

21. A use as claimed in claim 20, wherein the diabetes is  
5 postprandial hyperglycemia.

22. A use as claimed in any one of claims 17 to 19, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

23. A use as claimed in any one of claims 17 to 19, wherein  
10 the disease associated with hyperglycemia is diabetic complications.

24. A use as claimed in any one of claims 17 to 19, wherein the disease associated with hyperglycemia is obesity.